Lauren Sciences LLC has received an AU$1 million grant from FightMND to advance its development of LAUR-301, a novel V-Smart Nanomedicine for ALS. The therapy aims to protect motor neurons and induce neuro-restoration, slowing or reversing the disease.
The ALS Association granted Lauren Sciences LLC its third award for developing LAUR-301, a V-Smart Nanomedicine for ALS. LAUR-301 aims to deliver GDNF across the blood-brain barrier and induce neuro-restoration in all ALS patients.
Lauren Sciences LLC has received the second grant from Voices Against Brain Cancer to continue developing LAUR-401, its innovative V-Smart Nanomedicine for Glioblastoma Multiforme. The award confirms the successful development of LAUR-401 and anticipates its potential as a transformative therapeutic for brain cancer patients.
Lauren Sciences will use the grant to customize LAUR-301 with neurotrophic factor and deliver it to disease sites in central nervous system ALS mice. The company aims for LAUR-301 to enter human clinical trials and become a transformative V-Smart TM Nanomedicine for treating ALS.
V-Smart Nanomedicine for glioblastoma multiforme (GBM) will target and deliver a known chemotherapeutic across the blood brain barrier, providing an effective new treatment option. The grant supports the development of this transformative therapeutic for brain cancer patients.
The ALS Association granted Lauren Sciences LLC a grant to develop a V-Smart therapeutic for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The project aims to deliver neurotrophic factors across the blood brain barrier using the company's novel V-Smart nanovesicle platform technology.
The V-SmartTM therapeutic delivered tenofovir at levels considerably above therapeutic concentrations, overcoming the challenge of delivering HIV drugs through the BBB. The successful outcome confirms the strong potential of the delivery system to treat neuro-HIV and improve lives of AIDS patients.
Lauren Sciences LLC has received a second grant from the Michael J. Fox Foundation to further develop its V-Smart therapeutic platform for treating Parkinson's disease. The grant will investigate the efficacy of V-Smart vesicles in delivering GDNF to brain regions affected by PD.
Lauren Sciences LLC has received a grant from The Campbell Foundation to develop a V-Smart therapeutic for neuro-HIV. The treatment aims to deliver tenofovir across the blood brain barrier to treat viral reservoirs in the central nervous system.
The company will use the grant to develop a novel therapeutic for Parkinson's disease, targeting dopaminergic neurons with GDNF delivery. The goal is to improve patients' lives by treating or reversing the progression of the disease.